The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin infammation

Archives of Dermatological Research

Volumn 304, Issue 4, 2012, Pages 313-317

  Rundfeldt, Chris ^a   Steckel, Hartwig ^b   Sörensen, Torben ^b   Wlaź, Piotr ^c  

^a Drug ConsultNet   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Anti inflammatory; Arachidonic acid; Dibutyryl cyclo adenosine monophosphate; Inflammation; Mice

Indexed keywords

ARACHIDONIC ACID; BUCLADESINE; FASTUM GEL; KETOPROFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; EAR EDEMA; EMULSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFLAMMATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; BUCLADESINE; CYCLIC AMP; DERMATITIS; DISEASE MODELS, ANIMAL; EDEMA; EMULSIONS; HUMANS; MALE; MICE; TREATMENT OUTCOME;

EID: 84862904484     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-012-1216-6     Document Type: Article

References (20)

1. Anonymous (1988) Bucladesine sodium. Drug Data Rep 10(7):542
2. Asai J, Takenaka H, Katoh N, Kishimoto S (2006) Dibutyryl cAMP influences endothelial progenitor cell recruitment during wound neovascularization. J Invest Dermatol 126:1159-1167
3. Bartsch M, Zorn-Kruppa M, Kuhl N, Genieser HG, Schwede F, JastorV B (2003) Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells. Biol Chem 384:1321-1326 (Pubitemid 37168701)
4. Bäumer W, Gorr G, Hoppmann J, Ehinger AM, Rundfeldt C, Kietzmann M (2003) AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol 55:1107-1114 (Pubitemid 36998651)
5. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M (2007) Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 6:17-26 (Pubitemid 46488295)
6. Carbone A, Siu A, Patel R (2010) Pediatric atopic dermatitis: a review of the medical management. Ann Pharmacother 44:1448-145.
7. Giembycz MA (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155:288-290
8. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C (2008) An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 24:1529-1538 (Pubitemid 351741586)
9. Goyarts E, Mammone T, Muizzuddin N, Marenus K, Maes D (2000) Correlation between in vitro cyclic adenosine monophosphate phosphodiesterase inhibition and in vivo anti-inflammatory effect. Skin Pharmacol Appl Skin Physiol 13:86-92 (Pubitemid 30195377)
10. Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J (2002) Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 147:299-307
11. Hahn AU, Mittal KL (1979) Mechanism of demulsification of oilin- water emulsion in the centrifuge. Colloid Polym Sci 257:959-96.
12. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS, Weiner ES (1996) Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107:51-56 (Pubitemid 26236094)
13. Higgs G (2010) Is PDE4 too difficult a drug target? Curr Opin Investig Drugs 11:495-498
14. Hoppmann J, Bäumer W, Galetzka C, Hofgen N, Kietzmann M, Rundfeldt C (2005) The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol 57:1609-1617 (Pubitemid 41752275)
15. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase- 4 as a therapeutic target. Drug Discov Today 10:1503-1519 (Pubitemid 41527193)
16. Ogreid D, Ekanger R, Suva RH, Miller JP, Sturm P, Corbin JD, Doskeland SO (1985) Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination. Principles for optimizing the isozyme specificity of analog combinations. Eur J Biochem 150:219-227 (Pubitemid 15069797)
17. Okumura Y, Goto M, Kato H, Takayama S, Mafune E, Yamada A, Tanaka K, Watanabe M, Nonomura H (2003) Skin irritation studies on bucladesine sodium ointment containing a new fragrance in rabbits. Jap Pharmacol Ther 31:1031-1037 (Pubitemid 38404842)
18. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ (2011) Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 12:18
19. Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127-162 (Pubitemid 30394536)
20. Wollenberg A, Schnopp C (2010) Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am 30:351-368